Optimizing community linkage to care and antiretroviral therapy Initiation: Lessons from the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) and their adaptation in Nigeria ART Surge.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 11 05 2021
accepted: 01 09 2021
entrez: 20 9 2021
pubmed: 21 9 2021
medline: 24 11 2021
Statut: epublish

Résumé

Ineffective linkage to care (LTC) is a known challenge for community HIV testing. To overcome this challenge, a robust linkage to care strategy was adopted by the 2018 Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS). The NAIIS linkage to care strategy was further adapted to improve Nigeria's programmatic efforts to achieve the 1st 90 as part of the Nigeria Antiretroviral Therapy (ART) Surge initiative, which also included targeted community testing. In this paper we provide an overview of the NAIIS LTC strategy and describe the impact of this strategy on both the NAIIS and the Surge initiatives. The NAIIS collaborated with community-based organizations (CBOs) and deployed mobile health (mHealth) technology with real-time dashboards to manage and optimize community LTC for people living with HIV (PLHIV) diagnosed during the survey. In NAIIS, CBOs' role was to facilitate linkage of identified PLHIV in community to facility of their choice. For the ART Surge, we modified the NAIIS LTC strategy by empowering both CBOs and mobile community teams as responsible for not only active LTC but also for community testing, ART initiation, and retention in care. Of the 2,739 PLHIV 15 years and above identified in NAIIS, 1,975 (72.1%) were either unaware of their HIV-positive status (N = 1890) or were aware of their HIV-positive status but not receiving treatment (N = 85). Of these, 1,342 (67.9%) were linked to care, of which 952 (70.9%) were initiated on ART. Among 1,890 newly diagnosed PLHIV, 1,278 (67.6%) were linked to care, 33.7% self-linked and 66.3% were linked by CBOs. Among 85 known PLHIV not on treatment, 64 (75.3%) were linked; 32.8% self-linked and 67.2% were linked by a CBO. In the ART Surge, LTC and treatment initiation rates were 98% and 100%, respectively. Three-month retention for monthly treatment initiation cohorts improved from 76% to 90% over 6 months. Active LTC strategies by local CBOs and mobile community teams improved LTC and ART initiation in the ART Surge initiative. The use of mHealth technology resulted in timely and accurate documentation of results in NAIIS. By deploying mHealth in addition to active LTC, CBOs and mobile community teams could effectively scale up ART with real-time documentation of client-level outcomes.

Sections du résumé

BACKGROUND
Ineffective linkage to care (LTC) is a known challenge for community HIV testing. To overcome this challenge, a robust linkage to care strategy was adopted by the 2018 Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS). The NAIIS linkage to care strategy was further adapted to improve Nigeria's programmatic efforts to achieve the 1st 90 as part of the Nigeria Antiretroviral Therapy (ART) Surge initiative, which also included targeted community testing. In this paper we provide an overview of the NAIIS LTC strategy and describe the impact of this strategy on both the NAIIS and the Surge initiatives.
METHODS
The NAIIS collaborated with community-based organizations (CBOs) and deployed mobile health (mHealth) technology with real-time dashboards to manage and optimize community LTC for people living with HIV (PLHIV) diagnosed during the survey. In NAIIS, CBOs' role was to facilitate linkage of identified PLHIV in community to facility of their choice. For the ART Surge, we modified the NAIIS LTC strategy by empowering both CBOs and mobile community teams as responsible for not only active LTC but also for community testing, ART initiation, and retention in care.
RESULTS
Of the 2,739 PLHIV 15 years and above identified in NAIIS, 1,975 (72.1%) were either unaware of their HIV-positive status (N = 1890) or were aware of their HIV-positive status but not receiving treatment (N = 85). Of these, 1,342 (67.9%) were linked to care, of which 952 (70.9%) were initiated on ART. Among 1,890 newly diagnosed PLHIV, 1,278 (67.6%) were linked to care, 33.7% self-linked and 66.3% were linked by CBOs. Among 85 known PLHIV not on treatment, 64 (75.3%) were linked; 32.8% self-linked and 67.2% were linked by a CBO. In the ART Surge, LTC and treatment initiation rates were 98% and 100%, respectively. Three-month retention for monthly treatment initiation cohorts improved from 76% to 90% over 6 months.
CONCLUSIONS
Active LTC strategies by local CBOs and mobile community teams improved LTC and ART initiation in the ART Surge initiative. The use of mHealth technology resulted in timely and accurate documentation of results in NAIIS. By deploying mHealth in addition to active LTC, CBOs and mobile community teams could effectively scale up ART with real-time documentation of client-level outcomes.

Identifiants

pubmed: 34543306
doi: 10.1371/journal.pone.0257476
pii: PONE-D-21-15583
pmc: PMC8451986
doi:

Substances chimiques

Anti-Retroviral Agents 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0257476

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2010 Mar 04;5(3):e9538
pubmed: 20209059
Health Serv Insights. 2016 Oct 05;9:29-36
pubmed: 27721654
AIDS Care. 2021 Jan;33(1):70-79
pubmed: 32036678
MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):421-426
pubmed: 33764965
J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):522-526
pubmed: 28825941
Indian J Sex Transm Dis AIDS. 2014 Jan;35(1):1-11
pubmed: 24958979
J Int AIDS Soc. 2018 Jan;21(1):
pubmed: 29356376
HIV AIDS (Auckl). 2019 Dec 02;11:321-332
pubmed: 31819663
J Int AIDS Soc. 2017 Jul 18;20(1):21691
pubmed: 28782333
J Behav Med. 2019 Oct;42(5):883-897
pubmed: 30635862
J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):e90-4
pubmed: 24442233
Int J Infect Dis. 2019 Oct;87:185-192
pubmed: 31446175
Sage Open. 2020 Jan-Mar;10(1):
pubmed: 32719733
AIDS. 2012 Oct 23;26(16):2059-67
pubmed: 22781227
AIDS Res Treat. 2017;2017:5812650
pubmed: 29445545
AIDS Behav. 2019 Sep;23(Suppl 2):142-152
pubmed: 31197700
Curr Opin HIV AIDS. 2019 Nov;14(6):494-502
pubmed: 31408009
Stud Health Technol Inform. 2019 Jul 4;262:162-165
pubmed: 31349291
J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):453-460
pubmed: 28961678
HIV AIDS (Auckl). 2021 Aug 25;13:839-850
pubmed: 34471388
AIDS. 2019 Dec 15;33 Suppl 3:S213-S226
pubmed: 31490781
PLoS One. 2019 Nov 19;14(11):e0219032
pubmed: 31743336
J Int AIDS Soc. 2018 Apr;21(4):e25108
pubmed: 29675995
J Infect Dis. 2013 Nov 15;208(10):1624-8
pubmed: 23908493
AIDS Care. 2013;25 Suppl 1:S67-77
pubmed: 23745632
BMC Public Health. 2019 Apr 5;19(1):383
pubmed: 30953503
Soc Sci Med. 2017 Mar;176:52-59
pubmed: 28129547

Auteurs

Ibrahim Jahun (I)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Ishaq Said (I)

Maryland Global Initiatives (affiliate of the University of Maryland, Baltimore), Abuja, Federal Capital Territory, Nigeria.

Ibrahim El-Imam (I)

Maryland Global Initiatives (affiliate of the University of Maryland, Baltimore), Abuja, Federal Capital Territory, Nigeria.

Akipu Ehoche (A)

Maryland Global Initiatives (affiliate of the University of Maryland, Baltimore), Abuja, Federal Capital Territory, Nigeria.

Ibrahim Dalhatu (I)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Aminu Yakubu (A)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Stacie Greby (S)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Megan Bronson (M)

Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Kristin Brown (K)

Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Moyosola Bamidele (M)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Andrew T Boyd (AT)

Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Pamela Bachanas (P)

Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Emilio Dirlikov (E)

Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Chinedu Agbakwuru (C)

Maryland Global Initiatives (affiliate of the University of Maryland, Baltimore), Abuja, Federal Capital Territory, Nigeria.

Andrew Abutu (A)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Michelle Williams-Sherlock (M)

Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Denis Onotu (D)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Solomon Odafe (S)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Daniel B Williams (DB)

Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Orji Bassey (O)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Obinna Ogbanufe (O)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Chibuzor Onyenuobi (C)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Ayo Adeola (A)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Chidozie Meribe (C)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Timothy Efuntoye (T)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Omodele J Fagbamigbe (OJ)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Ayodele Fagbemi (A)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Uzoma Ene (U)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Tingir Nguhemen (T)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Ifunanya Mgbakor (I)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Matthias Alagi (M)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Olugbenga Asaolu (O)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Ademola Oladipo (A)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Joy Amafah (J)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Charles Nzelu (C)

Federal Ministry of Health, Abuja, Nigeria.

Patrick Dakum (P)

Institute of Human Virology (IHVN), Abuja, Federal Capital Territory, Nigeria.

Charles Mensah (C)

Institute of Human Virology (IHVN), Abuja, Federal Capital Territory, Nigeria.

Ahmad Aliyu (A)

Institute of Human Virology (IHVN), Abuja, Federal Capital Territory, Nigeria.

Prosper Okonkwo (P)

AIDS Prevention Initiative Nigeria (APIN), Abuja, Federal Capital Territory, Nigeria.

Bolanle Oyeledun (B)

Center for Integrated Health Program (CIHP), Abuja, Federal Capital Territory, Nigeria.

John Oko (J)

Catholic Caritas Foundation Nigeria (CCFN), Abuja, Federal Capital Territory, Nigeria.

Akudo Ikpeazu (A)

Federal Ministry of Health, Abuja, Nigeria.

Aliyu Gambo (A)

National Agency for the Control of AIDS, Abuja, Federal Capital Territory, Nigeria.

Manhattan Charurat (M)

Maryland Global Initiatives (affiliate of the University of Maryland, Baltimore), Abuja, Federal Capital Territory, Nigeria.

Tedd Ellerbrock (T)

Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Sani Aliyu (S)

National Agency for the Control of AIDS, Abuja, Federal Capital Territory, Nigeria.

Mahesh Swaminathan (M)

Centers for Disease Control and Prevention-Nigeria Country Office, Abuja, Federal Capital Territory, Nigeria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH